Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Leukemia, Myeloid, Acute 40Leukemia 30Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28Hematologic Neoplasms 23Leukemia, Lymphocytic, Chronic, B-Cell 16Lymphoma 11Febrile Neutropenia 10Myelodysplastic Syndromes 9Recurrence 8Neoplasms 8Lymphoma, Non-Hodgkin 8Leukemia, Myeloid, Chronic-Phase 8Leukemia, Promyelocytic, Acute 7Neoplasm, Residual 6Neutropenia 5Neoplasms, Plasma Cell 4Graft vs Host Disease 4Philadelphia Chromosome 3Mycoses 3Lymphoma, Mantle-Cell 3Leukemia, B-Cell 3Invasive Fungal Infections 3Bronchiolitis Obliterans Syndrome 3Blast Crisis 3Waldenstrom Macroglobulinemia 2Vomiting 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Tumor Lysis Syndrome 2

Interventions

rasburicase 2Urate Oxidase 2Uric Acid 1Pegloticase 1Oxidoreductases 1Carbamates 1Amides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Tumor Lysis Syndrome × Other hematologic neoplasm × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Sanofi

Phase 4 Completed
94 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡